Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Andrx

Executive Summary

Andrx: Controlled-release oral drug developer files for initial public offering with the Securities & Exchange Commission of 1.7 mil. shares of common stock at a price estimated between $11 and $13 a share. Oppenheimer and Gruntal are managing underwriters for the IPO. Proceeds will be used primarily for the establishment of a commercial-scale manufacturing facility for Fort Lauderdale-based Andrx' generic versions of Cardizem CD and Dilacor XR. ANDAs for the products are on file with FDA...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel